|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Several apoptosis regulation genes have been mapped to this region, including Tumor Protein 73 (p73), DNA Fragmentation Factor subunits alpha (DFFA) and beta (DFFB), and Tumor Necrosis Factor Receptor Superfamily Members 9 and 25 (TNFRSF9, TNFRSF25).
|
16156899 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prophylactic vaccination with 56 °C-treated TRAMP-C2 tumour cells alone provided protection against TRAMP-C2 tumour growth in vivo, whilst in the therapeutic regimen, control of tumour growth was achieved combining immunization with adjuvant chemotherapy.
|
29752021 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, in a tumor therapy model, Ad-tWT1 vaccination of TRAMP-C2 tumor-bearing mice significantly suppressed tumor growth.
|
19351755 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, direct injection of Ad-G/iCasp1 into s.c. TRAMP-C2 tumors caused focal but extensive apoptosis without evidence for a bystander effect at the maximal viral dose (i.e., 2.5 x 10(10) viral particles/25 microl) in host animals that also received CID compared with control animals.
|
11289132 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, immunisation with RALA/pPSCA loaded MNs elicited a tumour-specific immune response against TRAMP-C1 tumours ex vivo.
|
31299353 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By analyzing the chromosomal map of this region, we found TNFRSF12 as a candidate tumor suppressor gene.
|
11532517 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast to the B16/F10, TRAMP-C2 tumors had an extracellular matrix with significantly higher levels of MMP2 and MMP9 expression and activity.
|
17131319 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The gadolinium-doped iron oxide nanoparticles (GdIONP) with greater specific power adsorption rate (SAR) than Fe<sub>3</sub>O<sub>4</sub> was developed and its potential application in tumour therapy and particle tracking were demonstrated in transgenic adenocarcinoma of the mouse prostate C1 (TRAMP-C1) tumours.
|
28540811 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combination therapy with this hypoxia-prodrug and checkpoint blockade cooperated to cure more than 80% of tumors in the transgenic adenocarcinoma of the mouse prostate-derived (TRAMP-derived) TRAMP-C2 model.
|
30188869 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, ABC294640 diminished the growth rate of TRAMP-C2 xenografts in syngeneic hosts and elevated dihydroceramides within tumors as visualized by MALDI imaging mass spectroscopy.
|
26494858 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, development of prostate carcinomas in TRAMP/Rosa26-FoxM1b double TG mice required high levels of FoxM1 protein to overcome sustained expression of the alternative reading frame tumor suppressor, a potent inhibitor of FoxM1 transcriptional activity.
|
16452231 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In both TRAMP and HONDA tumor xenografts, the combination therapy of G47Delta with androgen ablation led to significantly enhanced inhibition of the tumor growth and prolonged survival.
|
16278413 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Depletion of AGS3 in the TRAMP-C1 cells (TRAMP-C1-AGS3-/-) decreased cell proliferation and delayed wound healing and tumor growth in both C57BL/6 (~3-fold) and nude mice xenografts, relative to control TRAMP-C1 cells.
|
31215992 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The ASC-MDA7 only reduced tumor growth in the TRAMP-C2-Ras (TC2Ras) prostate cancer model.
|
21671747 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cross-referencing differentially expressed TRAMP genes to public human prostate array datasets revealed 66 genes with concordant expression in mouse and human PCa; 56 between metastases and normal and 10 between primary tumor and normal tissues.
|
18668517 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, a TRAMP-derived Orthotopic Prostate Syngeneic (TOPS) mouse model was developed and found to provide a consistent means of monitoring tumor and metastatic responses to novel treatments.
|
29450905 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Prostate tumor cells implanted in mice deficient in atrial natriuretic peptide receptor A (NPRA-KO) failed to grow, and treatment of TRAMP-C1 xenografts with iNPRA reduced tumor burden and MIF expression.
|
21586128 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Daily intake of this herbal product significantly suppressed the tumor size (<i>P</i> = 0.0368) with lower histopathologic scores (<i>P</i> = 0.0364) in TRAMP mice, which were associated with an increase in both splenocyte cytotoxicity against tumor cells and numbers of CD8 T cells, macrophages, and dendritic cells in the spleens <i>in vivo</i>.
|
29861778 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, transfection efficiency of a plasmid co-expressing hSef-b/eGFP into TRAMP C2 tumors was 14.7 ± 2.5% following a single TUS application.
|
29118380 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Five mice bearing TRAMP-C1 tumor were half-irradiated with a dose of 15 Gy.
|
28176411 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By breeding TRAMP mice with S100A9 knock-out (S100A9(-/-)) animals and scoring the appearance of palpable tumors we observed a delayed tumor growth in animals devoid of S100A9 expression.
|
22470535 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ω3-enriched diet decreased prostate TRAMP-C2 tumor growth in immune-competent eugonadal and castrated mice.
|
30073695 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The effect of thrombin on tumor cell cycle activation and spontaneous growth was examined in synchronized serum-starved tumor cell lines and a model of spontaneous prostate cancer development in TRAMP mice.
|
19351827 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, PTX3 overexpression in transgenic mice or treatment with the FGF inhibitor NSC12 result in a significant inhibition of the growth and vascularization of TRAMP-C2 tumor grafts, a murine model of prostate cancer, that were paralleled by a decrease of mast cell infiltrate into the lesion.
|
29137286 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Regardless of initial tumor size intratumor rVSV-DeltaG-SV5-F administration in mice bearing subcutaneous TRAMP-C2 tumors resulted in a significantly reduced tumor load over that of the nonfusogenic green fluorescent control virus and of heat inactivated recombinant vesicular stomatitis virus in treated animals (p <0.01).
|
20172545 |
2010 |